ADVERTISEMENT
OTC Pain Creams and Sunscreens Recalled
ARG Laboratories Inc. is recalling a handful of over-the-counter pain-relieving creams and protective sunscreens for being out of specification for active ingredients, according to the June 5, 2024, US Food and Drug Administration (FDA) Enforcement Report.
The recalled products were distributed throughout the United States. They include the following two products, which were affected by a “violative grade of propylene glycol used during the manufacturing process,” according to the FDA:
- Pain Wizard (camphor 3%, menthol 3%), natural relief for muscular & arthritic pain, enriched with capsaicin, camphor, menthol & MSM, in 16-fluid-ounce bottles (UPC 8 63865 00012 3), from lot 18723C3 (Exp. 6/30/25); 8-ounce tubes (UPC 8 63865 00011 6), from lots 19823C4 (Exp. 7/31/25) and 01623C1 (Exp. 1/31/25); 4-ounce tubes (UPC 8 63865 00019 2), from lot 06023C1 (Exp. 1/31/25); and 3-fluid-ounce roll-on (UPC 8 63865 00010 9), from lot 17323C3 (Exp. 6/30/25); and
- Golden Tiger Natural Pain Relieving Cream (camphor 3%, menthol 3%), enriched with capsaicin, aloe vera, willow bark & MSM, in 128-fluid-ounce jugs (UPC 1 82294 00005 5), from lot 01823C2 (Exp. 1/31/25); 32-fluid-ounce bottles with pump (UPC 1 82294 00004 8), from lots 01823C2 and 01823C1 (Exp. 1/31/25); 4-ounce tubes (UPC 1 82294 00002 4), from lot 01623C1 (Exp. 1/31/25); and 3-fluid-ounce roll-on (UPC 1 82294 00006 2), from lot 17323C3 (Exp. 6/30/25).
The following sunscreens were also included in the recall:
- Bull Frog SPF 50 Amphibious Lotion, broad-spectrum sunscreen with UVA/UVB protection, 5 fluid ounces (UPC 8 50016 52112 5), from lots 08623C2 and 08923C2 (Exp. 3/31/26); and
- Aloe Gator (octocrylene 8%, octyl methoxycinnamate 6%, benzophone-3 6%, octyl salicylate 5%), manufactured for AGS Brands, original formula, SPF 40+, broad-spectrum protective gel, sport performance, 1 ounce (no UPC provided), from lot 04023C1 (Exp. 1/31/25); and 4 ounces (UPC 0 17971 10421 7), from lot 04023C1 (Exp. 1/31/25).
ARG Laboratories voluntarily initiated the recalls on April 17, 2024. On May 30, 2024, the FDA designated them Class II. Per the classification, use of the recalled products may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.
